NovoCure (NVCR) Change in Receivables (2017 - 2023)

NovoCure (NVCR) has reported Change in Receivables for 7 consecutive years, with -$2.6 million the latest figure, recorded in Q3 2023.

• Quarterly Change in Receivables rose 77.07% year-over-year to -$2.6 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was -$20.3 million (down 165.14% YoY) and the FY2022 annual result came in at -$2.5 million, up 51.67% from the prior year.
• Change in Receivables grew to -$2.6 million in Q3 2023 per NVCR's latest filing, from -$6.9 million in the prior quarter.
• Over the last five years, Change in Receivables for NVCR reached as high as $19.7 million in Q1 2020 and fell as low as -$14.5 million in Q1 2023.
• A 5-year average of $1.8 million and a median of $2.0 million in 2019 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2020 — Change in Receivables jumped 868.47% — and 2022, when it plunged 409.23%.
• Year by year, Change in Receivables stood at $19.5 million in 2019, then tumbled by 116.44% to -$3.2 million in 2020, then soared by 57.93% to -$1.3 million in 2021, then surged by 379.96% to $3.8 million in 2022, then slumped by 170.06% to -$2.6 million in 2023.
• According to Business Quant data, Change in Receivables over the past three periods registered -$2.6 million, -$6.9 million, and -$14.5 million for Q3 2023, Q2 2023, and Q1 2023 respectively.